CN113272017A - 抗tim-3抗体 - Google Patents

抗tim-3抗体 Download PDF

Info

Publication number
CN113272017A
CN113272017A CN201980086657.5A CN201980086657A CN113272017A CN 113272017 A CN113272017 A CN 113272017A CN 201980086657 A CN201980086657 A CN 201980086657A CN 113272017 A CN113272017 A CN 113272017A
Authority
CN
China
Prior art keywords
antibody
tim
variable region
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980086657.5A
Other languages
English (en)
Chinese (zh)
Inventor
章东
赵新燕
安琦
D·南那曼
R·萨娜杰迪诺夫
V·苏德
C·伊夫兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN113272017A publication Critical patent/CN113272017A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980086657.5A 2018-11-01 2019-11-01 抗tim-3抗体 Pending CN113272017A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754383P 2018-11-01 2018-11-01
US62/754,383 2018-11-01
PCT/US2019/059555 WO2020093023A1 (en) 2018-11-01 2019-11-01 Anti-tim-3 antibodies

Publications (1)

Publication Number Publication Date
CN113272017A true CN113272017A (zh) 2021-08-17

Family

ID=69159931

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980086657.5A Pending CN113272017A (zh) 2018-11-01 2019-11-01 抗tim-3抗体

Country Status (8)

Country Link
US (1) US20220081480A1 (https=)
EP (1) EP3873611A1 (https=)
JP (1) JP2022505925A (https=)
CN (1) CN113272017A (https=)
AU (1) AU2019371457A1 (https=)
CA (1) CA3117429A1 (https=)
IL (1) IL282707A (https=)
WO (1) WO2020093023A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023040940A1 (zh) * 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7214440B2 (ja) * 2018-11-01 2023-01-30 三菱重工エンジニアリング株式会社 検証処理装置、検証処理方法及びプログラム
US20240391997A1 (en) * 2021-07-16 2024-11-28 Brightpath Biotherapeutics Co., Ltd. Anti-tim-3 antigen antibody or antibody derivative, and use thereof
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
KR20250034101A (ko) 2022-07-01 2025-03-10 트랜스진 계면활성제-단백질-d 및 tnfsf의 구성원을 포함하는 융합 단백질
WO2025202222A1 (en) 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2026059950A1 (en) * 2024-09-10 2026-03-19 Agilent Technologies, Inc. Anti-human tim3 antibodies for in vitro diagnostics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013818A2 (en) * 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018126233A1 (en) * 2016-12-29 2018-07-05 Development Center For Biotechnology Anti-human tim-3 antibodies and methods of use thereof
TW201831196A (zh) * 2017-01-09 2018-09-01 美商提薩羅有限公司 用抗tim-3抗體治療癌症之方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US9676863B2 (en) 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
US10259874B2 (en) * 2014-10-27 2019-04-16 Agency For Science, Technology And Research Anti-TIM-3 antibodies
US20180153986A1 (en) * 2015-04-24 2018-06-07 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
EP3878465A1 (en) * 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3370768B9 (en) * 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
SG11201903867YA (en) * 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
AU2018264455B2 (en) 2017-05-12 2024-12-12 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-beta receptor and medicinal uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013818A2 (en) * 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018126233A1 (en) * 2016-12-29 2018-07-05 Development Center For Biotechnology Anti-human tim-3 antibodies and methods of use thereof
TW201831196A (zh) * 2017-01-09 2018-09-01 美商提薩羅有限公司 用抗tim-3抗體治療癌症之方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CATHERINE A. SABATOS-PEYTON ET AL.: "Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy", 《ONCOIMMUNOLOGY》, vol. 7, no. 2, pages 1 - 9 *
岳翠华等: "抗人TIM-3 单克隆抗体的纯化及其体外生物学功能的研究", 《临床检验杂志》, vol. 36, no. 5, pages 375 - 379 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023040940A1 (zh) * 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症

Also Published As

Publication number Publication date
US20220081480A1 (en) 2022-03-17
AU2019371457A1 (en) 2021-05-20
JP2022505925A (ja) 2022-01-14
CA3117429A1 (en) 2020-05-07
EP3873611A1 (en) 2021-09-08
WO2020093023A1 (en) 2020-05-07
IL282707A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
KR102839330B1 (ko) Pd-1에 대한 단일-도메인 항체 및 이의 변이체
RU2734771C2 (ru) Нейтрализация ингибиторных путей в лимфоцитах
CN113272017A (zh) 抗tim-3抗体
JP2021524268A (ja) Ｐｄ−ｌ１及びｃｄ１３７に結合する抗体分子
AU2018366650A1 (en) Single-domain antibodies and variants thereof against PD-L1
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
CN113301961A (zh) 给予抗tim-3抗体的方法
AU2020363041B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
CN114981301B (zh) Pd1和vegfr2双结合剂
WO2019084307A1 (en) ANTI-MERTK ANTIBODIES AND METHODS OF USE
KR20220071264A (ko) 항-pd-l1 항원 결합 단백질 및 이의 응용
WO2019089753A2 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
CN119569881B (zh) 抗cd39抗体及其用途
KR20190117467A (ko) IFN-γ-유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
KR20230158058A (ko) 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
HK40058527A (en) Anti-tim-3 antibodies
HK40059550A (en) Methods of administering anti-tim-3 antibodies
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
KR20240051277A (ko) PD-L1, CD137, 및/또는 TGFβ에 대한 이중특이체 및 삼중특이체 결합 단백질 및 이의 용도
HK40113788A (zh) 抗cd39抗体及其用途
CN114901695A (zh) 抗gitr抗体及其用途
EA049949B1 (ru) Лечение рака

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058527

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210817

WD01 Invention patent application deemed withdrawn after publication